Photo taken from: https://ascopubs.org/doi/10.1200/JCO.23.02166
Mar 31, 2024, 23:12
Stephen V Liu: Results from phase III CONTACT-01 trial Journal of Clinical Oncology
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X:
“Results from phase III CONTACT-01 trial Journal of Clinical Oncology. Randomized 186 pts with NSCLC and prior chemo and immunotherapy to either atezolizumab + cabozantinib or standard docetaxel. Atezo/cabo did not improve OS (10.7m vs 10.5m, HR 0.88, ns) & was more toxic.”
Source: Stephen V Liu/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12